Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee

Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01874574

Enrollment

100

Registered

2013-06-11

Start date

2011-01-31

Completion date

2013-09-30

Last updated

2014-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

Knee Osteoarthritis, Corticosteroid, Hyaluronic acid, Intra-articular injection

Brief summary

Corticosteroid and Hylan G-F 20 are both effective in improving pain and function of osteoarthritic knee patients.

Detailed description

Corticosteroid and Hylan G-F 20 are both effective in improving pain and function of osteoarthritic knee patients up to 6 months.

Interventions

DRUGHylan G-F 20

After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.

DRUGCorticosteroid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of knee OA * Knee pain for most days of the prior month * Radiographic evidence consistent with knee OA * Aged between 40 and 80 years old

Exclusion criteria

* Lumbar spondylosis * Gross deformity of the knee * Co-existent inflammatory or crystal arthritis * Prior knee surgery * Injury to the knee in the preceding 6 months * Any intra-articular injection in the preceding 3 months * Pregnant or Lactating * Current infection in the affected knee * Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
WOMAC Score	6 months	Change from Baseline in WOMAC score at 6 months

Secondary

Measure	Time frame	Description
Visual Analogue Scale(VAS)	6 months	Change from Baseline in VAS score at 6 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026